DexCom, Inc. (DXCM): Price and Financial Metrics
DexCom, Inc. (DXCM)
Today's Latest Price: $408.36 USD
Updated Sep 30 3:25pm
Add DXCM to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 140 in Medical - Devices & Equipment
See all "A" rated Strong Buy stocks
DXCM Stock Summary
- With a market capitalization of $38,505,600,811, Dexcom Inc has a greater market value than 95.07% of US stocks.
- DXCM's current price/earnings ratio is 188.11, which is higher than 96.29% of US stocks with positive earnings.
- Price to trailing twelve month operating cash flow for DXCM is currently 97.68, higher than 96.7% of US stocks with positive operating cash flow.
- Stocks that are quantitatively similar to DXCM, based on their financial statements, market capitalization, and price volatility, are ANSS, YNDX, ILMN, NTES, and Z.
- Visit DXCM's SEC page to see the company's official filings. To visit the company's web site, go to www.dexcom.com.
DXCM Stock Price Chart Technical Analysis Charts
DXCM Price/Volume Stats
| Current price | $408.36 | 52-week high | $456.23 |
| Prev. close | $402.18 | 52-week low | $145.23 |
| Day low | $397.51 | Volume | 368,656 |
| Day high | $415.63 | Avg. volume | 1,271,227 |
| 50-day MA | $416.85 | Dividend yield | N/A |
| 200-day MA | $335.49 | Market Cap | 39.10B |
DexCom, Inc. (DXCM) Company Bio
DexCom focuses on the design, development, and commercialization of continuous glucose monitoring systems for patients with diabetes. The company was founded in 1999 and is based in San Diego, California.
DXCM Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $408.36 | $377.37 | -6% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Dexcom Inc. To summarize, we found that Dexcom Inc ranked in the 43th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 5.5%. In terms of the factors that were most noteworthy in this DCF analysis for DXCM, they are:
- The stock's equity weight, or the proportion of capital from equity relative to debt, is 96. Its equity weight surpasses that of 74.82% of free cash flow generating stocks in the Healthcare sector.
- The company's compound free cash flow growth rate over the past 5.42 years comes in at 0.85%; that's greater than 88.87% of US stocks we're applying DCF forecasting to.
- The business' balance sheet reveals debt to be 4% of the company's capital (with equity being the remaining amount). Approximately merely 13.37% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -8% |
| 1% | -7% |
| 2% | -6% |
| 3% | -5% |
| 4% | -4% |
| 5% | -3% |
HBIO, ITGR, CNC, IART, and PRAH can be thought of as valuation peers to DXCM, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...